MMTC Micro Imaging Technology Inc (CE)

Micro Imaging Technology Inc. (OTC:MMTC) announced that it will be working in collaboration with Richard L. Walker DVM, Ph.D., professor of Clinical Diagnostic Bacteriology and director of the California Animal Health and Food Safety (CAHFS) Laboratory located at the University of California at Davis, in projects to further demonstrate the efficacy of its laser-based microbe detection technology. CAHFS is the backbone of the Western Institute for Food Safety and Security whose mission is to conduct research that enhances food safety and defense in all sectors of the food systems' continuum from environment to consumer. The first project will involve the exact identification of specific characteristics of the E. coli bacteria at the strain level. This program expands on MIT's earlier demonstrated successes in the ability, within several minutes of testing, to determine subspecies of E. coli. The objective is to rapidly determine the level of resistivity of the bacteria to various antigens. According to Dr. Walker, "Such a study could interest audiences in a number of fields, including medical and food safety." About Micro Imaging Technology: The company has developed and patented a laser-based technology for rapid microbe detection and identification. The system measures scattered light intensity as individual microbes pass through a laser beam. The intensity pattern of the scattered light is a direct consequence of the size, shape and external and internal optical characteristics of the microbe. MIT has demonstrated the ability to detect and immediately identify the microbes Escherichia coli, Listeria, Salmonella Staphylococcus aureus, Shigella and other pathogenic bacteria. The company has verified its bacteria identification process by an independent, internationally recognized biological testing laboratory which designed and performed a comparative test that measured the accuracy, speed and efficiency of MIT's rapid microbe identification system against conventional gas chromatographic and biological processes. The comparative tests were in a double-blind experiment, meaning that the independent laboratory technicians, using the MIT system and the well-recognized alternative processes, were not aware of the various microbes' identity. The Test Report, in the company's opinion, demonstrated superbly the accuracy, speed and efficiency of the MIT system over conventional processes. The Report is available from the company. This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.